Brief Summary

Skip to Participation Criteria

This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3 mg bimatoprost and 5 mg timolol) by their physician.

• Study Type: Observational
• Study Design: Observational Model: Cohort, Time Perspective: Prospective
• Study Primary Completion Date: June 2011

Interventions Used in this Clinical Trial

• Drug: Fixed combination 0.3 mg bimatoprost and 5 mg timolol
  • Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry

Arms, Groups and Cohorts in this Clinical Trial

• POAG or OHT
  • Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry

Outcome Measures for this Clinical Trial

Primary Measures

• Change From Baseline in Intraocular Pressure (IOP)
  • Time Frame: Baseline, 18 Weeks
    Safety Issue?: No

Secondary Measures

• Physician Assessment of Tolerability Using a 4-Point Scale
  • Time Frame: 18 Weeks
    Safety Issue?: No
• Patient Assessment of Tolerability Using a 4-Point Scale
  • Time Frame: 18 Weeks
    Safety Issue?: No
• Physician Assessment of Adherence to GANfort®
  • Time Frame: 18 Weeks
    Safety Issue?: No
• Patients Continuing With GANfort® After 18 Weeks
  • Time Frame: 18 Weeks
    Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

• Diagnosis of primary open angle glaucoma or ocular hypertension
• Prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol)

Exclusion Criteria

• None

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

• Lead Sponsor
  • Allergan
• Provider of Information About this Clinical Study
  • Sponsor
• Overall Official(s)
  • Medical Director, Study Director, Allergan